QUOTE AND NEWS
TheStreet.com  May 8  Comment 
NEW YORK (TheStreet) -- Shares of Fluidigm were falling 26.4% to $27.54 on heavy trading volume Friday after the medical laboratories and research company missed analysts' estimates for earnings and revenue in the first quarter. Fluidigm...
Benzinga  May 8  Comment 
Mizuho Securities downgraded Fluidigm Corporation (NASDAQ: FLDM) from Buy to Neutral. The price target for Fluidigm has been lowered from $50.00 to $30.00. Fluidigm shares have gained 25.18 percent over the past 52 weeks, while the S&P 500...
GenEng News  Jan 14  Comment 
Fluidigm, a pioneer of single-cell biology, has announced a new technology that enables individual cells to be analyzed in situ, enabling greater understanding of systems biology at the cellular and subcellular levels. “We want to ignite a...
TheStreet.com  Dec 16  Comment 
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.  TheStreet Ratings quantitative algorithm...
TheStreet.com  Nov 17  Comment 
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.  TheStreet Ratings quantitative algorithm...
Forbes  Nov 10  Comment 
Investors eyeing a purchase of Fluidigm Corp (NASD: FLDM) shares, but cautious about paying the going market price of $29.09/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...




 
TOP CONTRIBUTORS

Fluidigm (NASDAQ:FLDM) makes microfluidic systems which are used in the life sciences and agricultural biotechnology industries. The company's microfluidic systems are instruments such as chips and reagents used in laboratories. These systems decrease costs, increase output, and allow the laboratory to run processes that would normally be infeasible. Fluidigm has increased the number of fluid components on a single chip which allows the laboratory to run complex experiments on a smaller surface area. Fluidigm has sold its products to 200 different customers across 20 different countries.[1]

In addition to cutting cost for its clients, Fluidigm also allows them to run experiments normally not possible. Laboratories can conduct 24 times more gene expression experiments and 36,960 simultaneous reactions on a single fluidic chip.[2] Fluidigm's chips also improve data quality as each individual fluid compartment are highly homogeneous. This allows for different conditions to be tested across a single chip without conditions ranging from compartment to compartment.[3]

The company's initial public offering of stock on the NASDAQ occurred on February 9, 2011. The company offered 5.6M shares each for $13.50. The inital price range was $13.50-$15.50. This brought the deal size to $75M. The company had originally planned to sell 5.2M shares, but increased its offer to 5.6M. The lead underwriter of the deal were Deutsche Bank AG (DB) and Piper Jaffray Companies (PJC).[4]

For the first 9 months of 2010, the company's total revenue was $36M. The company reported a net loss for the same time period of $13.8M. This was largely due to a high Research & Development expense. For the first 9 months of 2010, the company spent $10M on research and development.[5]

References

  1. FLDM S-1/A 2011 PROSPECTUS OVERVIEW "Overview" pg 1
  2. FLDM S-1/A 2011 PROSPECTUS OVERVIEW "Overview" pg 2
  3. FLDM S-1/A 2011 PROSPECTUS OVERVIEW "The Fluidigm Solution" pg 3-4
  4. Renaissance Capital - IPO Home "Fluidigm prices upsized IPO at $13.50, the low end of the range" 10 Feb 2011
  5. FLDM S-1/A 2011 PROSPECTUS OVERVIEW "SUMMARY CONSOLIDATED FINANCIAL DATA" pg 9
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki